ID: h-0f41864d88
Hypothesis
TREM2-independent neuronal protection via cystatin-C/LRP2 signaling
Cystatin C directly protects neurons against excitotoxicity through LRP2 (megalin) receptor engagement and AKT/ERK survival signaling.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Cystatin C directly protects neurons against excitotoxicity through LRP2 (megalin) receptor engagement and AKT/ERK survival signaling. Critical weaknesses: neuronal LRP2 expression is technically challenging to detect and primarily studied in developmental contexts; systemic cystatin C must cross both BBB and neuronal membrane to engage LRP2—a two-membrane traversal problem with low probability.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Amyloid-beta Plaques<br/>Phospholipid Ligands"]
B["TREM2 Receptor<br/>Ligand Binding"]
C["TYROBP/DAP12<br/>ITAM Phosphorylation"]
D["SYK Kinase<br/>Activation"]
E["PLCG2<br/>IP3 + DAG Generation"]
F["Ca2+ Release<br/>Cytoskeletal Remodeling"]
G["Microglial Phagocytosis<br/>Plaque Compaction"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix3 supports3 contradicts
Supports
Differential downstream signaling in microglia lacking Alzheimer's-related TREM2 or its adaptor TYROBP/DAP12.
Contradicts
High circulating cystatin C in renal disease associated with mortality, not neuroprotection
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CST3
No curated PDB or AlphaFold mapping for CST3 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CST3/LRP2/AKT/ERK from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CST3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.4%
Volatility
Low
0.0197
Events (7d)
2
Price History
▲12.0%💾 Resource Usage
LLM Tokens
11,154
$0.0335
Total Cost
$0.0335
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF primary cortical neurons are subjected to LRP2 CRISPR knockout, THEN exogenously applied cystatin C will fail to protect against NMDA-induced excitotoxicity compared to wild-type neurons, with at l | LDH release ≤20% in WT+cystatin C vs ≥40% in LRP2-KO+cystatin C; MTT viability ≥70% in WT+cystatin C vs ≤40% in LRP2-KO+cystatin C | — no observation — | pending | 0.45 |
| IF adult mice receive neuron-specific LRP2 knockout (CamKII-Cre;LRP2flox), THEN systemic cystatin C administration (1mg/kg/day i.p. for 7 days) will fail to reduce cerebral infarct volume following 60 | Infarct volume reduction of ≥35% in WT mice receiving cystatin C vs vehicle; no significant reduction (<15%) in neuronal LRP2-KO mice receiving cystatin C | — no observation — | pending | 0.38 |
🔮 Falsifiable Predictions (2)
pendingconf 45%
IF primary cortical neurons are subjected to LRP2 CRISPR knockout, THEN exogenously applied cystatin C will fail to protect against NMDA-induced excitotoxicity compared to wild-type neurons, with at least 50% reduction in neuroprotective effect.
Predicted outcome: LDH release ≤20% in WT+cystatin C vs ≥40% in LRP2-KO+cystatin C; MTT viability ≥70% in WT+cystatin C vs ≤40% in LRP2-KO+cystatin C
Falsification: Equal neuroprotection (LDH release ≤25% in both conditions) observed in LRP2-KO neurons after cystatin C treatment would disprove LRP2 requirement
pendingconf 38%
IF adult mice receive neuron-specific LRP2 knockout (CamKII-Cre;LRP2flox), THEN systemic cystatin C administration (1mg/kg/day i.p. for 7 days) will fail to reduce cerebral infarct volume following 60-min transient MCAO compared to vehicle-treated knockout mice.
Predicted outcome: Infarct volume reduction of ≥35% in WT mice receiving cystatin C vs vehicle; no significant reduction (<15%) in neuronal LRP2-KO mice receiving cystat
Falsification: Cystatin C reducing infarct volume by ≥30% in neuron-specific LRP2 knockout mice would directly contradict the hypothesis that neuronal LRP2 mediates cystatin C neuroprotection
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.